Novartis v. Eugia Pharma: Tasigna Nilotinib Dismissed Without Prejudice in 18 Days
Novartis AG filed suit against Eugia Pharma Specialities in Delaware asserting six patents covering nilotinib hydrochloride capsules — the active ingredient in its blockbuster cancer drug Tasigna. The case was voluntarily dismissed without prejudice just 18 days after filing, with each party bearing its own costs.
Six-Patent Tasigna Suit Dropped in 18 Days — Strategic Pause or Settlement Signal?
On 27 June 2025, Novartis AG and Novartis Pharmaceuticals Corporation filed a patent infringement action against Eugia Pharma Specialities Ltd. in the Delaware District Court (Case No. 1:25-cv-00800) before Judge Gregory B. Williams. The complaint asserted six US patents — US8389537B2, US9061029B2, US8163904B2, US8293756B2, US8415363B2, and US8501760B2 — each directed to nilotinib hydrochloride, the active pharmaceutical ingredient in Tasigna, Novartis’s oncology product indicated for chronic myeloid leukaemia.
On 15 July 2025 — just 18 days after filing — Novartis filed a notice of voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i), dropping all claims without prejudice. Each party was left to bear its own attorneys’ fees and costs. A Rule 41(a)(1)(A)(i) dismissal requires no court order and takes effect upon filing, meaning no merits adjudication occurred and no judicial findings were made regarding infringement, validity, or claim scope.
The 18-day lifecycle is notably brief even by ANDA-related dismissal standards, where cases often resolve pre-trial but typically after months of litigation. The speed and the ‘without prejudice’ designation leave the public record silent on whether a licensing agreement, covenant not to sue, or separate commercial arrangement was reached. The absence of defendant counsel of record and the lack of any docket activity beyond the initial filing and dismissal notice is consistent with a negotiated resolution reached before formal litigation commenced.
Filing to Voluntary dismissal in 18 days
18 days — among the shortest lifecycle cases in Delaware pharma patent litigation
Voluntarily dismissed: what Rule 41 without prejudice means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral right to exit before answer
Under Fed. R. Civ. P. 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order by filing a notice before the opposing party serves an answer or a motion for summary judgment. The dismissal takes effect immediately upon filing. No judicial findings are made on infringement, validity, or damages — the case is erased from the merits standpoint as if it never proceeded.
No merits rulingWithout prejudice: Novartis retains the right to refile
A dismissal ‘without prejudice’ preserves the plaintiff’s right to bring the same claims again in a future action. This is legally distinct from a dismissal ‘with prejudice,’ which would bar refiling on the same patents and product. The public record here is silent on whether any agreement conditions the future exercise of that right — patent holders sometimes accept covenants not to sue or licensing terms that render refiling commercially unnecessary, but no such arrangement has been publicly disclosed.
Refiling right preservedEugia faces no injunction — but patent cloud remains
Eugia Pharma escapes this litigation without an adverse judgment and without any finding of infringement. However, because the dismissal is without prejudice, Novartis’s six asserted patents remain enforceable and the litigation threat is not extinguished. Eugia’s path to commercialising its generic nilotinib capsules (50 mg, 150 mg, 200 mg) may still depend on resolution of underlying patent rights, whether through licensing, expiry, or future proceedings.
No adverse findingGeneric nilotinib market entry remains uncertain
The rapid, without-prejudice dismissal suggests the parties may have reached a private arrangement — common in ANDA-related pharmaceutical litigation where brand-generic settlements often include negotiated market entry dates. Until Eugia or Novartis discloses launch timing or licensing terms, the commercialisation timeline for generic Tasigna capsules in the US market remains unclear. Competing generic filers for nilotinib should monitor any subsequent FDA approval or launch announcements closely.
Market entry date unknownFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Global pharmaceutical company — holder of six nilotinib (Tasigna) patentsSearch in Eureka ↗ |
| Defendant | Eugia Pharma Specialities, Ltd. | Company | Indian generic pharmaceutical manufacturer seeking to market nilotinib hydrochloride capsulesSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice states that ‘Plaintiffs Novartis Pharmaceuticals Corporation and Novartis AG hereby dismiss all claims… without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i).’ The Rule 41(a)(1)(A)(i) mechanism requires no court order and produces no merits determination — no findings on infringement or validity attach to either party. The equal costs allocation is standard for this dismissal type and does not signal which party was in a stronger legal position. The without-prejudice designation is the operative term: it preserves Novartis’s full right to reassert all six nilotinib patents against Eugia in future proceedings.
US8389537B2 and five further patents — nilotinib hydrochloride formulations (Tasigna)
The six asserted patents — US8389537B2, US9061029B2, US8163904B2, US8293756B2, US8415363B2, and US8501760B2 — collectively form Novartis’s US patent estate around nilotinib hydrochloride, the BCR-ABL tyrosine kinase inhibitor marketed as Tasigna for chronic myeloid leukaemia (CML). The patents span compound claims, formulation claims, and method-of-treatment claims, creating a multi-layered barrier to generic entry. The application dates range from filings associated with the mid-to-late 2000s, suggesting protection extending well into the 2020s for at least some family members.
Tasigna is one of Novartis’s flagship oncology assets, and the breadth of the six-patent assertion against a single ANDA filer reflects a standard brand-pharma portfolio defence strategy. For generic manufacturers, each patent in the set represents an independent invalidity or non-infringement hurdle. The assertion of both formulation and compound patents is particularly significant: even a reformulated generic product may face exposure under compound or method claims. Competitors in the CML treatment space — including other ANDA filers for nilotinib — should treat this six-patent cluster as the baseline enforcement landscape.
Should your team run an FTO against Novartis’s nilotinib patent estate?
Any company developing, manufacturing, or seeking regulatory approval for generic nilotinib hydrochloride capsules — including 50 mg, 150 mg, and 200 mg dosage forms — should conduct a rigorous freedom-to-operate analysis against all six patents asserted in this case. The without-prejudice dismissal means Novartis retains full enforcement rights, and the rapid filing demonstrates Novartis’s willingness to litigate immediately upon ANDA submission. This applies equally to other generic applicants not party to this action.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to map claim scope across all six asserted patents simultaneously, identify design-around opportunities at the formulation and compound level, and benchmark against the full Novartis nilotinib portfolio beyond the six litigated patents. Eureka’s citation graph and patent family tools also surface related international filings that may affect market entry planning in EU, UK, and other jurisdictions where Tasigna is approved.
Run a freedom-to-operate analysis on US8389537B2 to assess your product’s exposure
Run FTO in Eureka →Similar nilotinib and oncology small-molecule patent cases in Delaware
Explore patent infringement cases involving nilotinib, BCR-ABL inhibitors, and ANDA-related oncology drug litigation filed in Delaware District Court.
What this case signals for the nilotinib and oncology generics IP landscape
An 18-day voluntary dismissal across six pharma patents raises questions every oncology IP team should be asking.
Speed of dismissal suggests pre-litigation negotiation was already advanced
When a multi-patent pharmaceutical action is voluntarily dismissed under Rule 41(a)(1)(A)(i) within 18 days — before defendant counsel even appears — it typically signals that commercial discussions were underway before suit was filed, or resolved almost immediately after. Generic entrants and brand holders in the nilotinib space should treat this as a marker of active portfolio management by Novartis rather than litigation failure.
Six patents asserted: Novartis’s nilotinib portfolio is broad and actively defended
The assertion of six distinct US patents against a single ANDA filer signals that Novartis is deploying a layered patent strategy around Tasigna. R&D teams and IP counsel at generic pharma companies targeting nilotinib should conduct thorough freedom-to-operate analysis against all six asserted patents, as any one of them could independently support a future infringement claim if Novartis refiles.
Novartis v Eugia — key questions answered
Novartis AG and Novartis Pharmaceuticals Corporation filed suit against Eugia Pharma Specialities Ltd. in Delaware District Court on 27 June 2025, asserting six US patents covering nilotinib hydrochloride (Tasigna). On 15 July 2025 — 18 days after filing — Novartis voluntarily dismissed all claims without prejudice under Rule 41(a)(1)(A)(i). Each party bears its own costs. No merits determination was made.
A without-prejudice dismissal under Rule 41(a)(1)(A)(i) means Novartis retains the right to refile the same infringement claims against Eugia in a future action. No judicial findings on infringement or patent validity were made. This is legally distinct from a with-prejudice dismissal, which would permanently bar Novartis from reasserting those six patents against Eugia for the same product.
Novartis asserted six US patents: US8389537B2, US9061029B2, US8163904B2, US8293756B2, US8415363B2, and US8501760B2. All six relate to nilotinib hydrochloride, the active ingredient in Tasigna capsules. The asserted product was generic nilotinib hydrochloride capsules in 50 mg, 150 mg, and 200 mg strengths.
The public record does not disclose the reason for the 18-day dismissal. Cases dismissed this rapidly under Rule 41(a)(1)(A)(i) — before defendant counsel even appears — are often consistent with a negotiated resolution reached before or immediately after filing, potentially including a licensing agreement or negotiated market entry date. However, no such arrangement has been publicly confirmed.
Yes. Because the dismissal was without prejudice, Novartis retains the legal right to assert the same six patents against Eugia for the same generic nilotinib products in a future action. Whether Novartis will do so depends on commercial and licensing factors not disclosed in the public record. A second voluntary dismissal of the same claims would, however, operate as a dismissal with prejudice under Rule 41(a)(1)(B).
PatSnap Eureka searches patents and litigation data to answer instantly.